Ovos' Former IND Homotaurine Strikes Out As Dietary Ingredient
This article was originally published in The Tan Sheet
FDA rejects Ovos Natural Health's citizen petition to classify homotaurine as a dietary ingredient, but leaves the door open for future attempts on the pathway Ovos tried to navigate – moving a substance from failed investigational new drug to dietary supplement.
You may also be interested in...
International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.
Supplement industry stakeholders say FDA makes an unjustifiable regulatory move by stating that the widely used dietary supplement ingredient is noncompliant, while the finding compels the agency to reverse its earlier acceptance of NDI notifications for vinpocetine.
FDA’s rejection of PharmaRoth Labs’ Sucanon NDI notifications included a suggestion that the firm try the investigational new drug pathway, but is not a sign of a growing trend at the agency.